T-cell receptor-Major Histocompatibility Complex class II-peptide complex (TCR-MHC II-peptide)

The T-cell receptor-Major Histocompatibility Complex class II-peptide complex (TCR-MHC II-peptide) is the fundamental molecular assembly that initiates the adaptive immune response in CD4+ helper T-cells (Janeway's Immunobiology, 2016). This complex forms when a T-cell receptor (TCR) recognizes a specific antigenic peptide fragment bound within the groove of a Major Histocompatibility Complex class II (MHC II) molecule on the surface of an antigen-presenting cell (StatPearls, MHC Class II, 2023). The interaction is stabilized by the CD4 co-receptor, which binds to the non-polymorphic region of the MHC II molecule, facilitating intracellular signaling through the CD3 complex (UniProt, P01730). This recognition event is highly specific and governs the T-cell's ability to distinguish between self and non-self antigens, making it a critical checkpoint in immune homeostasis (PubMed, PMID: 25144338). In autoimmune conditions like Rheumatoid Arthritis or Type 1 Diabetes, the TCR-MHC II-peptide complex inappropriately recognizes self-peptides, triggering chronic inflammation (Nature Reviews Immunology, 2017). Conversely, in oncology, the presentation of neoantigens via this complex is essential for effective anti-tumor immunity and is the basis for many cancer vaccines (Science, 2015). Therapeutic interventions targeting this complex include peptide-based glatiramoids that compete for MHC II binding and TCR-mimetic antibodies designed to target specific pMHC complexes (Journal of Clinical Investigation, 2020).

Other names

TCR-pMHCII complexCD4+ T-cell recognition complexMHC class II-restricted T-cell receptorTCR-MHC II complex

Competitive inhibition of antigen presentation, TCR-CD3 complex modulation, T-cell activation inhibition, Calcineurin inhibition, Co-stimulation blockade